NL

Thomas Koch

This inventor holds 0 USPTO granted patents, plus 1 CIPO patent.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Thomas Koch. Retrieved from https://idiyas.com/inventor/thomas-koch-h0iyzw0n

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 1.0

ph-index = 1


Loading Chart...

Title: Thomas Koch - Innovator in Estetrol Synthesis

Introduction

Thomas Koch is a notable inventor based in the Netherlands. He has made significant contributions to the field of chemistry, particularly in the synthesis of estetrol. His innovative approach to this process showcases his expertise and dedication to advancing industrial applications.

Latest Patents

Thomas Koch holds a patent titled "Synthesis Of Estetrol Via Estrone Derived Steroids." This patent outlines a process for producing estetrol starting from a 3-A-oxy-estra1,3,5(10),15-tetraen-17-one. The method involves using an alkyl group, preferably a methyl group, or a benzylic group, preferably a benzyl group. This process is particularly suitable for industrial applications.

Career Highlights

Thomas Koch is currently associated with Pantarhei Bioscience B.V., where he continues to work on innovative projects. His career reflects a commitment to research and development in the pharmaceutical industry.

Collaborations

Some of his notable coworkers include Mark Theodoor Verhaar and Erwin Gerardus Warmerdam. Their collaboration contributes to the advancement of research and innovation within their field.

Conclusion

Thomas Koch's work in the synthesis of estetrol demonstrates his valuable contributions to the field of chemistry. His innovative processes have the potential to impact industrial applications significantly.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…